Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy

S. M. Larson, J. A. Carrasquillo, Kenneth Krohn

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

33 patients with advanced malignant melanoma were studied after intravenous administration of 131I-labeled Fab fragments specific for p97, an oncofetal glycoprotein of human melanoma. In all, 47 gamma camera imaging studies were performed for the purpose of localization of metastatis deposits. In addition to tumor, 131I-Fab uptake was also seen in liver and kidney. 20 of these studies included stimultaneous administration of both an 131I-labeled Fab specific for p97, and an 125I-labeled Fab not specific for p97. Blood clearance of p97-specific Fab was significantly more rapid than for nonspecific Fab. Eight of these patients had biopsies of subcutaneous nodules at 48 and 72 h postinjection in order to assess whether localization of radioactivity was antigen specific. Antigen-specific localization was observed with average ratios of specific/nonspecific uptake of 3.7 (48 h) and 3.4 (72 h); uptake was strongly correlated with tumor p97 concentration (r = 0.81, P <0.01). Also, imaging studies of the biodistribution of 131I-labeled anti-p97 Fab in patients selected for high p97 tumor concentration showed avid tumor uptake and more prolonged retention of labeled Fab in tumor than in normal tissues. Based on these studies, we estimated that total 131I doses of 500 mCi could be safely given to patients before dose-limiting toxicity would be observed. Accordingly, in seven selected patients, phase I radiotherapeutic trials were begun. For improved radiation safety, we developed automated methods to label Fab fragments with up to 200 mCi of 131I. So far, a total of 12 individual therapeutic doses, ranging from 34 to 197 mCi of 131Ci of 131I-labeled to 5 to 10 mg of Fab, have been administered with excellent tumor localization and without major target organ toxicity. Cumulative doses ranged from 132 to 529 mCi 131I. Side effects attributable to the radiation were mild, with a transient drop slightly >50% in platelet and absolute neutrophil counts being observed in the two patients who received cumulative doses >500 mCi. In the combined series of 47 diagnostic and 12 therapeutic studies, four acute reactions were observed: one episode each of transient chills and fever; flushing and hypotension, and two skin rashes. All of these reactions responded promptly to symptomatic therapy. After multiple administrations of 131I-(anti-p97) Fab (IgG1), isotype-specific immunity was observed in three patients. In two of these patients it was possible to successfully reinfuse after immunity had developed with 131I-(anti-p97) Fab of a different isotype (IgG2a). Dosimetry estimates were performed based on the biodistribution of 131-Fab in these patients, and for every 100 mCi of 131I-Fab given, tumor received 1,040 rads; liver, 325 rads; and bone marrow, 30 rads. Marrow would be expected to be the critical organ, if doses >500 mCi 131I-Fab are given. These studies demonstrated that, with proper precautions, large doses (of an 131I-labeled murine Fab fragments immunologically specific for a human melanoma-associated antigen) could be safely given to humans by using repetitive intravenous injections.

Original languageEnglish (US)
Pages (from-to)2101-2114
Number of pages14
JournalJournal of Clinical Investigation
Volume72
Issue number6
StatePublished - 1983
Externally publishedYes

Fingerprint

Immunoglobulin Fab Fragments
Melanoma
Radiotherapy
Immunity
Bone Marrow
Melanoma-Specific Antigens
Antigens
Neoplasms
Chills
Liver
Exanthema
Intravenous Injections
Radionuclide Imaging
Intravenous Administration
Hypotension
Radioactivity
Glycoproteins
Neutrophils
Fever
Blood Platelets

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. / Larson, S. M.; Carrasquillo, J. A.; Krohn, Kenneth.

In: Journal of Clinical Investigation, Vol. 72, No. 6, 1983, p. 2101-2114.

Research output: Contribution to journalArticle

@article{7a0562a76d99412fbd4701cb234ccda9,
title = "Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy",
abstract = "33 patients with advanced malignant melanoma were studied after intravenous administration of 131I-labeled Fab fragments specific for p97, an oncofetal glycoprotein of human melanoma. In all, 47 gamma camera imaging studies were performed for the purpose of localization of metastatis deposits. In addition to tumor, 131I-Fab uptake was also seen in liver and kidney. 20 of these studies included stimultaneous administration of both an 131I-labeled Fab specific for p97, and an 125I-labeled Fab not specific for p97. Blood clearance of p97-specific Fab was significantly more rapid than for nonspecific Fab. Eight of these patients had biopsies of subcutaneous nodules at 48 and 72 h postinjection in order to assess whether localization of radioactivity was antigen specific. Antigen-specific localization was observed with average ratios of specific/nonspecific uptake of 3.7 (48 h) and 3.4 (72 h); uptake was strongly correlated with tumor p97 concentration (r = 0.81, P <0.01). Also, imaging studies of the biodistribution of 131I-labeled anti-p97 Fab in patients selected for high p97 tumor concentration showed avid tumor uptake and more prolonged retention of labeled Fab in tumor than in normal tissues. Based on these studies, we estimated that total 131I doses of 500 mCi could be safely given to patients before dose-limiting toxicity would be observed. Accordingly, in seven selected patients, phase I radiotherapeutic trials were begun. For improved radiation safety, we developed automated methods to label Fab fragments with up to 200 mCi of 131I. So far, a total of 12 individual therapeutic doses, ranging from 34 to 197 mCi of 131Ci of 131I-labeled to 5 to 10 mg of Fab, have been administered with excellent tumor localization and without major target organ toxicity. Cumulative doses ranged from 132 to 529 mCi 131I. Side effects attributable to the radiation were mild, with a transient drop slightly >50{\%} in platelet and absolute neutrophil counts being observed in the two patients who received cumulative doses >500 mCi. In the combined series of 47 diagnostic and 12 therapeutic studies, four acute reactions were observed: one episode each of transient chills and fever; flushing and hypotension, and two skin rashes. All of these reactions responded promptly to symptomatic therapy. After multiple administrations of 131I-(anti-p97) Fab (IgG1), isotype-specific immunity was observed in three patients. In two of these patients it was possible to successfully reinfuse after immunity had developed with 131I-(anti-p97) Fab of a different isotype (IgG2a). Dosimetry estimates were performed based on the biodistribution of 131-Fab in these patients, and for every 100 mCi of 131I-Fab given, tumor received 1,040 rads; liver, 325 rads; and bone marrow, 30 rads. Marrow would be expected to be the critical organ, if doses >500 mCi 131I-Fab are given. These studies demonstrated that, with proper precautions, large doses (of an 131I-labeled murine Fab fragments immunologically specific for a human melanoma-associated antigen) could be safely given to humans by using repetitive intravenous injections.",
author = "Larson, {S. M.} and Carrasquillo, {J. A.} and Kenneth Krohn",
year = "1983",
language = "English (US)",
volume = "72",
pages = "2101--2114",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy

AU - Larson, S. M.

AU - Carrasquillo, J. A.

AU - Krohn, Kenneth

PY - 1983

Y1 - 1983

N2 - 33 patients with advanced malignant melanoma were studied after intravenous administration of 131I-labeled Fab fragments specific for p97, an oncofetal glycoprotein of human melanoma. In all, 47 gamma camera imaging studies were performed for the purpose of localization of metastatis deposits. In addition to tumor, 131I-Fab uptake was also seen in liver and kidney. 20 of these studies included stimultaneous administration of both an 131I-labeled Fab specific for p97, and an 125I-labeled Fab not specific for p97. Blood clearance of p97-specific Fab was significantly more rapid than for nonspecific Fab. Eight of these patients had biopsies of subcutaneous nodules at 48 and 72 h postinjection in order to assess whether localization of radioactivity was antigen specific. Antigen-specific localization was observed with average ratios of specific/nonspecific uptake of 3.7 (48 h) and 3.4 (72 h); uptake was strongly correlated with tumor p97 concentration (r = 0.81, P <0.01). Also, imaging studies of the biodistribution of 131I-labeled anti-p97 Fab in patients selected for high p97 tumor concentration showed avid tumor uptake and more prolonged retention of labeled Fab in tumor than in normal tissues. Based on these studies, we estimated that total 131I doses of 500 mCi could be safely given to patients before dose-limiting toxicity would be observed. Accordingly, in seven selected patients, phase I radiotherapeutic trials were begun. For improved radiation safety, we developed automated methods to label Fab fragments with up to 200 mCi of 131I. So far, a total of 12 individual therapeutic doses, ranging from 34 to 197 mCi of 131Ci of 131I-labeled to 5 to 10 mg of Fab, have been administered with excellent tumor localization and without major target organ toxicity. Cumulative doses ranged from 132 to 529 mCi 131I. Side effects attributable to the radiation were mild, with a transient drop slightly >50% in platelet and absolute neutrophil counts being observed in the two patients who received cumulative doses >500 mCi. In the combined series of 47 diagnostic and 12 therapeutic studies, four acute reactions were observed: one episode each of transient chills and fever; flushing and hypotension, and two skin rashes. All of these reactions responded promptly to symptomatic therapy. After multiple administrations of 131I-(anti-p97) Fab (IgG1), isotype-specific immunity was observed in three patients. In two of these patients it was possible to successfully reinfuse after immunity had developed with 131I-(anti-p97) Fab of a different isotype (IgG2a). Dosimetry estimates were performed based on the biodistribution of 131-Fab in these patients, and for every 100 mCi of 131I-Fab given, tumor received 1,040 rads; liver, 325 rads; and bone marrow, 30 rads. Marrow would be expected to be the critical organ, if doses >500 mCi 131I-Fab are given. These studies demonstrated that, with proper precautions, large doses (of an 131I-labeled murine Fab fragments immunologically specific for a human melanoma-associated antigen) could be safely given to humans by using repetitive intravenous injections.

AB - 33 patients with advanced malignant melanoma were studied after intravenous administration of 131I-labeled Fab fragments specific for p97, an oncofetal glycoprotein of human melanoma. In all, 47 gamma camera imaging studies were performed for the purpose of localization of metastatis deposits. In addition to tumor, 131I-Fab uptake was also seen in liver and kidney. 20 of these studies included stimultaneous administration of both an 131I-labeled Fab specific for p97, and an 125I-labeled Fab not specific for p97. Blood clearance of p97-specific Fab was significantly more rapid than for nonspecific Fab. Eight of these patients had biopsies of subcutaneous nodules at 48 and 72 h postinjection in order to assess whether localization of radioactivity was antigen specific. Antigen-specific localization was observed with average ratios of specific/nonspecific uptake of 3.7 (48 h) and 3.4 (72 h); uptake was strongly correlated with tumor p97 concentration (r = 0.81, P <0.01). Also, imaging studies of the biodistribution of 131I-labeled anti-p97 Fab in patients selected for high p97 tumor concentration showed avid tumor uptake and more prolonged retention of labeled Fab in tumor than in normal tissues. Based on these studies, we estimated that total 131I doses of 500 mCi could be safely given to patients before dose-limiting toxicity would be observed. Accordingly, in seven selected patients, phase I radiotherapeutic trials were begun. For improved radiation safety, we developed automated methods to label Fab fragments with up to 200 mCi of 131I. So far, a total of 12 individual therapeutic doses, ranging from 34 to 197 mCi of 131Ci of 131I-labeled to 5 to 10 mg of Fab, have been administered with excellent tumor localization and without major target organ toxicity. Cumulative doses ranged from 132 to 529 mCi 131I. Side effects attributable to the radiation were mild, with a transient drop slightly >50% in platelet and absolute neutrophil counts being observed in the two patients who received cumulative doses >500 mCi. In the combined series of 47 diagnostic and 12 therapeutic studies, four acute reactions were observed: one episode each of transient chills and fever; flushing and hypotension, and two skin rashes. All of these reactions responded promptly to symptomatic therapy. After multiple administrations of 131I-(anti-p97) Fab (IgG1), isotype-specific immunity was observed in three patients. In two of these patients it was possible to successfully reinfuse after immunity had developed with 131I-(anti-p97) Fab of a different isotype (IgG2a). Dosimetry estimates were performed based on the biodistribution of 131-Fab in these patients, and for every 100 mCi of 131I-Fab given, tumor received 1,040 rads; liver, 325 rads; and bone marrow, 30 rads. Marrow would be expected to be the critical organ, if doses >500 mCi 131I-Fab are given. These studies demonstrated that, with proper precautions, large doses (of an 131I-labeled murine Fab fragments immunologically specific for a human melanoma-associated antigen) could be safely given to humans by using repetitive intravenous injections.

UR - http://www.scopus.com/inward/record.url?scp=0020973474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020973474&partnerID=8YFLogxK

M3 - Article

C2 - 6196380

AN - SCOPUS:0020973474

VL - 72

SP - 2101

EP - 2114

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -